Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA

Perche, Federico; Benvegnu, Thierry; Berchel, Mathieu; Lebegue, Loic; Pichon, Chantal; Jaffrès, Paul‐Alain; Midoux, Patrick

doi:10.1016/j.nano.2010.12.010

Cited by 198 publications

(200 citation statements)

References 51 publications

Supporting

Mentioning

191

Contrasting

Order By: Relevance

“…Mannosylated lipoplexes containing Man-His-C4-Chol functioned similarly to galactosylated lipoplexes containing Gal-His-C4-Chol, and showed a higher transfection activity than conventional mannosylated lipoplexes, via a mannose receptor-mediated mechanism both in vivo and in vitro. These results are consistent with those recently reported by Perche et al [188]. Therefore, both biodistribution and intracellular distribution could be useful strategies to obtain high gene expression in macrophages and/or dendritic cells.…”

Section: Nucleic Acid Deliverysupporting

confidence: 93%

“…Mannose-containing phospholipids from the cell wall of mycobacteria [175] and synthetic mannosylated lipids [176][177][178][179][180][181][182][183][184][185][186][187][188][189][190][191] have been used to prepare mannosylated liposomes for drug delivery or imaging of macrophages and/or dendritic cells. formamide (Man-C4-Chol), a galactosylated cholesterol derivative, to prepare mannosylated liposomes [179].…”

Section: Development Of Mannosylated Liposomesmentioning

confidence: 99%

“…The use of nucleic acids, DNA or mRNA vaccination for cytotoxic T lymphocyte induction [188,199,200,211], CpG DND for cancer immunotherapy [196,201], and NF-κB decoy delivery for anti-inflammatory therapy [H195, 203] has been reported. Fig.…”

Section: Nucleic Acid Deliverymentioning

confidence: 99%

See 2 more Smart Citations

Glycosylation-mediated targeting of carriers

Kawakami

Hashida

2014

Journal of Controlled Release

View full text Add to dashboard Cite

For safe and effective therapy, drugs should be delivered selectively to their target tissues or cells at an optimal rate. Drug delivery system technology maximizes the therapeutic efficacy and minimizes unfavorable drug actions by controlling their distribution profiles. Ligand-receptor binding is a typical example of specific recognition mechanisms in the body; therefore, ligand-modified drug carriers have been developed for active targeting based on receptor-mediated endocytosis. Among the various ligands reported thus far, sugar recognition is a promising approach for active targeting because of their high affinity and expression. Glycosylation has been applied for both macromolecular and liposomal carriers for cell-selective drug targeting.Recently, the combination of ultrasound exposure and glycosylated bubble liposomes has been developed. In this review, recent advances of glycosylation-mediated targeted drug delivery systems are discussed.

show abstract

Section: Nucleic Acid Deliverysupporting

confidence: 93%

Section: Development Of Mannosylated Liposomesmentioning

confidence: 99%

See 1 more Smart Citation

Glycosylation-mediated targeting of carriers

Kawakami

Hashida

2014

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…Lipid-based delivery of mRNA to DCs can be enhanced using mannosylated lipids and mannosylated/histidylated lipoplexes [102,103]. Another successful modification was to coat pH-responsive polymer particles with a lipid envelope [104], but this approach adsorbed the mRNA to the surface of the particles, which could prove problematic due to the sensitivity of mRNA to RNAases.…”

Section: Rnaimentioning

confidence: 99%

Functional RNA Delivery Targeted to Dendritic Cells By Synthetic Nanoparticles

McCullough¹,

Bassi²,

Démoulins³

et al. 2012

Therapeutic Delivery

102

View full text Add to dashboard Cite

ReviewTargeting the immune system Dendritic cells (DCs) play crucial roles in promoting and regulating immune defenses, providing important targets for prophylactic and therapeutic approaches (FiguRe 1). Particulate formulations, including liposomes and other nanoparticles, have been employed as delivery vehicles. Despite the large number of reports, current in-depth knowledge on the cellular processes involved remains relatively limited, particularly for nucleic acid delivery. Certain structures in the nucleic acid may also signal the cell in the sense of an adjuvant or immunomodulatory activity. Importantly, the optimized characteristics for delivery of an antigen or therapeutic agent may be distinct from those for nucleic acid delivery, especially RNA species. Moreover, RNA delivery for interference therapy will not necessarily require the same delivery routes as mRNA delivery wherein RNA translation is the main requisite.The efficacy of delivery can be further improved by targeting the appropriate cells of the immune system, an area in which nanoparticle-based delivery platforms have found an important niche [1]. Advances with prophylactic applications can also prove valuable for therapeutic applications and vice versa, as seen with RNA delivery. This review will consider how growing knowledge on delivery mechanisms has found application with nucleic acids, in both prophylaxis and therapy, focusing on interaction with DCs.The initial components of the DC endocytic pathways are critically important in determining how the cell handles the delivered material; thereafter, correct cytosolic delivery is a critical element for a number of desired outcomes, including delivery of nucleic acids. Advances made with protein delivery -in particular, vaccines -are of value to highlight the potential of a particular mode of application or the high risk for nucleic acid integrity. Particularly pertinent is the application of cationic elements in the delivery mechanisms and how application of ligands for cell receptors influence intracellular compartmentalization.It is not the aim of the present review to retrace all the fine details of work contributing to our current knowledge. Accordingly, review articles covering areas that have already received considerable attention will be employed and assimilated to provide a more elaborate picture of the current situation. This will allow a focusing on more recent advances, along with problems and pitfalls therein. While advances on protein and DNA delivery will be presented, these will be used to highlight how our current knowledge can be applied to RNA delivery. There are numerous reviews on protein delivery to DC, wherein many of the procedures employed are not relevant for RNA delivery, which must escape into the cytosol undamaged. With DNA delivery, there is also the question of whether the DNA will activate the DC or reach the nucleus for transcription; this latter area has most often Functional RNA delivery targeted to dendritic cells by synthetic nanoparticles Dendritic cell...

show abstract

“…This is a cost, labor and resource intensive procedure. Because of these reasons, researchers have explored alternative cell-based approaches 10,11 , as well as direct in vivo injection of mRNA in naked 12,13 and nanoparticle formats [14][15][16][17][18][19] . However, due to rapid degradation of naked mRNA in vivo, direct injection of mRNA is effective only when it is injected directly into lymph nodes 12,13 .…”

mentioning

confidence: 99%